Revolution Medicines (NASDAQ:RVMD) Stock Price Target Raised at TD Cowen

Revolution Medicines (NASDAQ:RVMD) had its price objective lifted by TD Cowen from $250.00 to $270.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price target would indicate a potential upside of 51.98% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Stifel Nicolaus upped their price target on Revolution Medicines from $215.00 to $230.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Wedbush lifted their price objective on shares of Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday, August 27th. Oppenheimer boosted their price objective on shares of Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. Bank of America cut their price objective on shares of Revolution Medicines from $265.00 to $264.00 and set a “buy” rating for the company in a research report on Friday, October 9th. Finally, Guggenheim raised their target price on shares of Revolution Medicines from $275.00 to $298.00 and gave the stock a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $251.19.

Revolution Medicines Stock Performance

RVMD traded down $22.04 on Thursday, hitting $177.66. 6,729,328 shares of the company traded hands, compared to its average volume of 2,800,308. The company has a 50 day moving average of $198.21 and a 200-day moving average of $156.90. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $38.08 billion, a PE ratio of -20.45 and a beta of 1.44. Revolution Medicines has a 12-month low of $58.91 and a 12-month high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, beating the consensus estimate of ($2.35) by $0.45. The company had revenue of $197.56 million during the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter last year, the business posted ($1.61) earnings per share. Sell-side analysts anticipate that Revolution Medicines will post -8.94 earnings per share for the current year.

Insider Buying and Selling at Revolution Medicines

In other news, Director Elizabeth Anderson sold 10,143 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $193.04, for a total value of $1,958,004.72. Following the completion of the transaction, the director owned 4,333 shares in the company, valued at $836,442.32. This trade represents a 70.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mark Goldsmith sold 80,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the completion of the sale, the insider owned 267,330 shares of the company’s stock, valued at $55,925,436. This trade represents a 23.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 290,991 shares of company stock worth $59,422,765. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors have recently modified their holdings of the company. Alphabet Inc. purchased a new position in Revolution Medicines in the 2nd quarter valued at approximately $551,843,000. Assenagon Asset Management S.A. raised its holdings in Revolution Medicines by 987.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock worth $447,710,000 after purchasing an additional 1,980,699 shares during the last quarter. ABS Investment Management LLC purchased a new stake in Revolution Medicines during the second quarter worth $337,104,000. Bank of America Corp DE purchased a new stake in Revolution Medicines during the second quarter worth $184,267,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Revolution Medicines by 82.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock worth $170,862,000 after purchasing an additional 411,740 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: The FDA approved and Revolution Medicines launched RASONQUE (daraxonrasib) for eligible patients with metastatic pancreatic cancer. The drug generated $198 million in net sales in the quarter, which included only a partial period after launch; the EU’s CHMP also recommended marketing authorization. Company results and progress update
• Positive Sentiment: Analysts raised price targets while maintaining bullish ratings: RBC to $321, Guggenheim to $298, Truist to $261 and Piper Sandler to $222. These upgrades signal confidence, though targets are opinions rather than guarantees. RBC target update
• Positive Sentiment: RVMD reported a third-quarter loss of $1.90 per share, narrower than the $2.35 loss analysts expected. Revenue of about $198 million also exceeded estimates, largely reflecting RASONQUE’s launch sales. Quarterly results
• Negative Sentiment: The quarterly loss widened from $1.61 per share a year earlier. Despite the consensus beat, the company remains loss-making, which may temper enthusiasm as investors assess its path toward sustained profitability.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.